Principal Financial Group Inc Cytokinetics Inc Transaction History

Principal Financial Group Inc

  • $172 Billion
  • Q3 2024

A detailed history of Principal Financial Group Inc transactions in Cytokinetics Inc stock. As of the latest transaction made, Principal Financial Group Inc holds 273,082 shares of CYTK stock, worth $13.4 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
273,082
Previous 393,579 30.62%
Holding current value
$13.4 Million
Previous $21.3 Million 32.39%
% of portfolio
0.01%
Previous 0.01%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 31, 2024
SELL
$51.22 - $60.16 $6.17 Million - $7.25 Million
-120,497 Reduced 30.62%
273,082 $14.4 Million
Q2 2024

Jul 29, 2024
SELL
$47.86 - $75.05 $1.82 Million - $2.85 Million
-37,977 Reduced 8.8%
393,579 $21.3 Million
Q1 2024

Apr 29, 2024
SELL
$63.75 - $108.06 $5.71 Million - $9.68 Million
-89,616 Reduced 17.2%
431,556 $30.3 Million
Q4 2023

Feb 07, 2024
SELL
$26.88 - $83.49 $110,503 - $343,227
-4,111 Reduced 0.78%
521,172 $43.5 Million
Q3 2023

Nov 02, 2023
SELL
$29.46 - $36.61 $896,526 - $1.11 Million
-30,432 Reduced 5.48%
525,283 $15.5 Million
Q2 2023

Aug 07, 2023
SELL
$32.62 - $40.75 $886,905 - $1.11 Million
-27,189 Reduced 4.66%
555,715 $18.1 Million
Q1 2023

May 09, 2023
SELL
$33.36 - $45.71 $2.75 Million - $3.77 Million
-82,480 Reduced 12.4%
582,904 $20.5 Million
Q4 2022

Feb 09, 2023
BUY
$35.77 - $51.11 $1.89 Million - $2.71 Million
52,937 Added 8.64%
665,384 $30.5 Million
Q3 2022

Nov 09, 2022
SELL
$38.54 - $54.52 $2.34 Million - $3.32 Million
-60,821 Reduced 9.03%
612,447 $29.7 Million
Q2 2022

Aug 10, 2022
BUY
$33.93 - $48.92 $513,021 - $739,670
15,120 Added 2.3%
673,268 $26.5 Million
Q1 2022

May 09, 2022
SELL
$29.74 - $46.0 $564,108 - $872,528
-18,968 Reduced 2.8%
658,148 $24.2 Million
Q4 2021

Feb 09, 2022
BUY
$34.35 - $46.38 $2.68 Million - $3.61 Million
77,885 Added 13.0%
677,116 $30.9 Million
Q3 2021

Nov 09, 2021
BUY
$18.54 - $35.74 $1.41 Million - $2.72 Million
76,150 Added 14.56%
599,231 $21.4 Million
Q2 2021

Aug 10, 2021
BUY
$19.79 - $26.99 $106,113 - $144,720
5,362 Added 1.04%
523,081 $10.4 Million
Q1 2021

May 10, 2021
BUY
$18.57 - $25.68 $13,073 - $18,078
704 Added 0.14%
517,719 $12 Million
Q4 2020

Feb 08, 2021
SELL
$15.26 - $28.61 $142,604 - $267,360
-9,345 Reduced 1.78%
517,015 $10.7 Million
Q3 2020

Nov 06, 2020
BUY
$20.58 - $28.96 $1.25 Million - $1.76 Million
60,673 Added 13.03%
526,360 $11.4 Million
Q2 2020

Aug 05, 2020
BUY
$11.15 - $24.64 $93,080 - $205,694
8,348 Added 1.83%
465,687 $11 Million
Q1 2020

May 12, 2020
SELL
$8.75 - $16.3 $157,561 - $293,514
-18,007 Reduced 3.79%
457,339 $5.39 Million
Q4 2019

Feb 05, 2020
BUY
$7.95 - $11.84 $99,605 - $148,343
12,529 Added 2.71%
475,346 $5.04 Million
Q3 2019

Nov 13, 2019
SELL
$10.82 - $14.25 $1,233 - $1,624
-114 Reduced 0.02%
462,817 $5.27 Million
Q2 2019

Aug 12, 2019
BUY
$7.95 - $11.25 $185,091 - $261,922
23,282 Added 5.3%
462,931 $5.21 Million
Q1 2019

May 10, 2019
SELL
$5.95 - $10.19 $26,947 - $46,150
-4,529 Reduced 1.02%
439,649 $3.56 Million
Q4 2018

Feb 14, 2019
SELL
$5.91 - $9.29 $30,075 - $47,276
-5,089 Reduced 1.13%
444,178 $2.81 Million
Q3 2018

Nov 14, 2018
BUY
$6.4 - $9.85 $284,492 - $437,852
44,452 Added 10.98%
449,267 $4.43 Million
Q2 2018

Aug 13, 2018
BUY
$6.9 - $9.9 $49,762 - $71,398
7,212 Added 1.81%
404,815 $0
Q1 2018

May 14, 2018
BUY
$7.2 - $10.05 $70,459 - $98,349
9,786 Added 2.52%
397,603 $2.86 Million
Q4 2017

Feb 13, 2018
SELL
$7.25 - $15.65 $495,320 - $1.07 Million
-68,320 Reduced 14.98%
387,817 $3.16 Million
Q3 2017

Nov 02, 2017
BUY
$12.0 - $15.0 $5.47 Million - $6.84 Million
456,137
456,137 $6.61 Million

Others Institutions Holding CYTK

# of Institutions
410
Shares Held
125M
Call Options Held
4.6M
Put Options Held
2.43M
View Full List

About CYTOKINETICS INC

CYTK Quotes by TradingView
  • Ticker CYTK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 94,144,096
  • Market Cap $4.62B
  • Description
  • Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...
More about CYTK
Track This Portfolio

Track Principal Financial Group Inc Portfolio

Follow Principal Financial Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Principal Financial Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email